Blinatumomab-based combination treatment for CD19-positive acute leukemia of an ambiguous lineage
10.3760/cma.j.cn121090-20240411-00133
- VernacularTitle:贝林妥欧单抗为基础的联合方案治疗CD19阳性系列模糊急性白血病的疗效分析
- Author:
Xiaoxia WU
1
;
Zhen YANG
1
;
Shenqi LU
1
;
Xinhui ZHANG
1
;
Aining SUN
1
;
Huifen ZHOU
1
;
Depei WU
1
;
Miao MIAO
1
Author Information
1. 苏州大学附属第一医院、江苏省血液病研究所、国家血液系统疾病临床医学研究中心、国家卫生健康委员会血栓与止血重点实验室，苏州 215006
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2024;45(11):1051-1054
- CountryChina
- Language:Chinese
-
Abstract:
Acute leukemia of ambiguous lineage (ALAL) is a rare type of acute leukemia and is extremely difficult to treat. Here, we present six patients with CD19-positive ALAL who were successfully treated with blinatumomab-based combination treatment in the front-line setting. Five were diagnosed with B-cell/myeloid mixed phenotype acute leukemia (MPAL) and one with B-cell/T cell MPAL. All six patients achieved complete remission after one cycle of blinatumomab combination treatment. Furthermore, 3 (50%) patients achieved MRD-negative (<0.01%) by flow cytometry and 2 (50%) of four patients with evaluable molecular MRD achieved molecular remission. At some point during the treatment, 5 (83.3%) patients achieved MRD negativity and all four patients with evaluable molecular MRD had molecular remission. The overall survival was 100%, and the event-free survival was 83.3% after a median follow-up time of 15 months. This study provides preliminary evidence that blinatumomab-based combination therapy is an effective and safe treatment for patients with CD19-positive ALAL in the front-line setting.
